Quarterly ResultMay 7, 2026, 08:22 AM
Harmony Biosciences Q1 Net Income $32.49M, EPS $0.55
AI Summary
Harmony Biosciences reported Q1 2026 net product revenue of $215.39 million, a 16.6% increase year-over-year. However, net income decreased by 28.7% to $32.49 million, and diluted EPS fell to $0.55, primarily due to a 100.9% surge in research and development expenses. The company entered into new license agreements with Novitium Pharma and MSN Laboratories, incurring upfront fees for future product development.
Key Highlights
- Net product revenue increased 16.6% to $215.39 million for Q1 2026.
- Net income decreased 28.7% to $32.49 million in Q1 2026.
- Diluted earnings per share (EPS) was $0.55, down from $0.78 year-over-year.
- Research and development expenses more than doubled to $69.38 million.
- Entered Novitium License Agreement with $15 million upfront fee in January 2026.
- Entered MSN License Agreement with $17 million upfront fee in February 2026.
- Cash and cash equivalents were $589.40 million as of March 31, 2026.
- Total stockholders' equity increased to $910.35 million as of March 31, 2026.